Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paraganglia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Paraganglia. Displaying page 1 of 1.
    EudraCT Number: 2010-024621-20 Sponsor Protocol Number: IGR2010/1715 Start Date*: 2013-03-26
    Sponsor Name:Institut Gustave Roussy
    Full Title: First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma
    Medical condition: Diagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses: 1. diagno...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033792 Paraganglion neoplasm NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002951-39 Sponsor Protocol Number: CAAA601A32201 Start Date*: Information not available in EudraCT
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheoc...
    Medical condition: somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073860 Paraganglioma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Trial now transitioned) PT (Prematurely Ended) PL (Trial now transitioned) BE (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003396-19 Sponsor Protocol Number: EOADR1-19 Start Date*: 2020-05-28
    Sponsor Name:Enterome
    Full Title: A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adr...
    Medical condition: - locally advanced or metastatic adrenocortical carcinoma (ACC) - malignant pheochromocytoma/paraganglioma (MPP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075444 Malignant paraganglioma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Ongoing) ES (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005028-13 Sponsor Protocol Number: MK-6482-015 Start Date*: 2021-07-19
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendoc...
    Medical condition: Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumor or von Hippel-Lindau (VHL) Disease-Associated Tumors or Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors with HIF...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10034876 Pheochromocytoma LLT
    20.0 100000004864 10073860 Paraganglioma LLT
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10047716 Von Hippel-Lindau disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004459-19 Sponsor Protocol Number: CDRB436G2401 Start Date*: 2019-07-31
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)
    Medical condition: Children and Adolescents with Cancers Harboring V600 mutations
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:14:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA